# Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer

> **NCT01438307** · PHASE2 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 28 (actual)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)
- Stage IV NSCLC
- Metastatic NSCLC

## Interventions

- **DRUG:** Cabazitaxel-XRP6258 (3-week cycle)
- **DRUG:** Cabazitaxel-XRP6258 (5-week cycle)

## Key facts

- **NCT ID:** NCT01438307
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2014-09
- **Final completion:** 2015-09
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2017-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01438307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01438307, "Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01438307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*